NCT01445535 2021-11-03
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
Clinical Trials
3 trialsNCT01902225 2020-06-09
Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma
University of California, San Francisco
Phase 1 Completed
NCT01490047 2015-06-16
Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas
Ludwig Institute for Cancer Research
Phase 1 Withdrawn